Related Experiment Video
Updated: Jul 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
DU-176b, an oral, direct Factor Xa antagonist
1Boston University Medical Center, Department of Medicine, 91 East Concord Street, Suite 200, Boston, MA 02118, USA. ehylek@bu.edu
Abstract:
Daiichi Sankyo Inc (formerly Daiichi Seiyaku Co Ltd) is developing DU-176b, a direct, orally active Factor Xa inhibitor, as an anticoagulant for the potential treatment of cardiovascular indications, including venous and arterial thrombosis. By January 2005, phase II studies had begun in the US and Europe, and by March 2006, phase II studies had begun in Japan. Phase II trials for the prevention of thromboembolism were ongoing in mid 2007.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antihypertensive Drugs: Direct Renin Inhibitors
Direct-Acting Cholinergic Agonists: Therapeutic Uses
